[18f]fdg-Le

Fludeoxyglucose (18F) is a radiopharmaceutical used in PET imaging for metabolic activity assessment. Commonly known as [18F]FDG, it helps detect cancer, brain disorders, and heart conditions. Short half-life requires prompt use after preparation.

Fludeoxyglucose (18F) is primarily used in positron emission tomography (PET) scans to identify areas of abnormal metabolic activity. It supports diagnosis of cancer, neurological disorders like epilepsy, and cardiac conditions such as reduced blood flow to the heart. [18F]FDG is also used in research settings to study brain function and other metabolic processes.

After intravenous injection, [18F]FDG is absorbed by cells with high glucose metabolism, such as the brain, heart, and certain tumors. The radiotracer emits positrons, which are detected by the PET scanner to create detailed images of metabolic activity. Patients may experience mild discomfort at the injection site.

This radiopharmaceutical should be handled by trained professionals in controlled medical environments. Pregnant or breastfeeding individuals should avoid exposure due to radiation risks. Patients should stay hydrated before the scan to aid tracer distribution and clearance. Avoid strenuous activity before the procedure.

No known drug interactions exist with [18F]FDG itself, but medications affecting glucose metabolism may influence scan results. Patients should inform providers about recent imaging procedures or medications containing iodine. Alcohol and caffeine consumption may impact metabolic activity in certain tissues.